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Introduction 
The epidermal growth factor system (EGF system) is present 
in various human organs. It has an important role in cell prolif-
eration, differentiation and apoptosis during embryogenesis and 
postnatal development [1, 2].
Dysregulation of  the EGF system signaling network is involved 
in cancer, diabetes, autoimmune, inflammatory, cardiovascular 
and nervous system disorders [1, 3].
Especially in cancer, the EGF system signaling network becomes 
hyperactivated with a variety of  mechanisms (ligand overproduc-
tion, receptor overproduction, constitutive receptor activation) 
[3, 4]. 
Furthermore, the EGF system in cancer contributes in prolifera-
tion, transformation, angiogenesis, migration and invasion [5]. 
Recent years the receptors of  the EGF system, are potential tar-
gets in cancer treatment [6, 7].
Molecular Biology of  ErbB Receptors
The EGF system has 4 receptors (EGFR, ErbB-2, ErbB-3 and 
ErbB-4) and numerous ligands [1, 4, 5].
ErbB receptors are trans-membrane glycoproteins and belong to 
the superfamily of  Receptor Tyrosine Kinases (RTKs) [1, 5]. They 
have an extracellular region with two ligand-binding domains, an 
extracellular juxtamembrane region, a hydrophobic transmem-
brane domain and an intracellular domain with tyrosine kinase 
activity [4, 8]. They catalyze the transfer of  the γ phosphate of  
ATP to the hydroxyl groups of  tyrosines in target proteins [9].
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The extracellular region of  EGFR, ErbB-3 and ErbB-4 has 2 dis-
tinct conformations. The closed conformation of  extracellular 
region is inactive. The open conformation of  extracellular region, 
is active and permits interactions with a ligand. In the absence of  
ligand binding, there is an equilibrium between the 2 conforma-
tions that favors the closed conformation [8, 10-12].
Ligand binding stabilizes the extracellular region in the open con-
formation, leads to the formation of  homodimeric and heterodi-
meric ErbB receptor complexes and activates ErbB receptors by 
an allosteric mechanism [8, 11-14]. That leads to intracellular ki-
nase activation and initiation of  downstream signaling pathways 
[4, 13, 15]. However, ErbB-3 has no intrinsic tyrosine kinase ac-
tivity and initiates signaling only in association with another ErbB 
receptor, usually ErbB-2 [16].
The extracellular region of  ErbB-2 has a conformation not suita-
ble for ligand binding [17]. However, ErbB-2 is capable for ligand 
independent dimerization and signaling [8, 17]. ErbB-2 heterodi-
merizes with other ErbB receptors and is their preferred heterodi-
merization partner [4, 13, 17]. Moreover, at elevated expression 
levels ErbB-2 homodimerizes [17]. 
Signaling Pathways of  ErbB Receptors
Dimerization of  ErbB receptors leads to intracellular kinase acti-
vation [4, 13, 15]. Subsequently, a number of  tyrosine residues in 
the COOH-terminal portion of  ErbB receptors becomes phos-
phorylated [5, 17, 18]. That phosphorylated tyrosine residues 
function as docking sites for cytoplasmic proteins containing Src 
homology 2 (SH2) and phosphotyrosine binding (PTB) domains 
[3, 4, 18]. Recruitment of  protein initiates intracellular signaling 
via several pathways:
1. Ras/Raf/mitogen-activated protein kinase (MAPK) pathway 
(regulates cell proliferation and survival) [Figure 1] [19, 20].
2. Phosphatidylinositol 3-kinase (PI3K)/Akt pathway (regu-
lates cell growth, apoptosis, tumor invasion, migration and 
resistance to chemotherapy) [Figure 1] [21, 22].
3. Signal transducers and activators of  transcription (STAT) 
pathway (regulates oncogenesis and tumor progression) [Fig-
ure 1] [23].
4. Src Kinase pathway (regulates cell proliferation, migration, 
adhesion, angiogenesis and immune function) [Figure 1] [24, 
25].
5. Phospholipase Cγ/protein kinase C pathway [Figure 1] [26, 
27].
Expression of  ErbB receptors in EC
Due to the inactive status of  postmenopausal endometrium, we 
expect to find significantly higher expression of  the 4 ErbB re-
ceptors in EC tissue [28].
EGFR localized to the basal part of  surface epithelial cells, only 
in stromal cells, or both, of  epithelial and stromal cells of  endo-
metrium [29-36]. It is primarily located in the cell membrane but 
also located in the cytoplasm [28, 32-40].
In unselected EC patients, there is EGFR expression in 43-67% 
of  cases [32-34, 36, 38-43]. In patients with Type I EC, there is 
EGFR expression in 46% of  cases [34]. In patients with Type II 
EC, there is EGFR expression in 34-50% of  cases [34, 35, 42, 
44, 45].
ErbB-2 localized base-laterally in the glands and surface epithelial 
cells of  endometrium [6, 29, 46]. It is located to the cell mem-
brane [8, 28, 32-36, 39, 47].
In unselected EC patients, ErbB-2 amplification/overexpression 
represents a rare event [43]. In patients with Type I EC, there is 
ΕrbB-2 receptor overexpression in 8% of  cases and Erb-2 gene 
amplification in 1.4-3% of  cases [42, 48]. Although ΕrbB-2 am-
plification/overexpression is ore common in patients with type II 
EC, the exact frequency remains controversial [34, 35, 42]. More-
over, there are racial differences regarding ErbB-2 overexpression 
in patients with type II EC [49]. ErbB-2 overexpression is more 
common in Black race patients with type II EC [49].
In patients with papillary serous EC, there is ΕrbB-2 receptor 
overexpression in 18%-80% of  cases and ΕrbB-2 gene amplifica-
tion in 17-47% of  cases [34, 35, 42, 48, 50-52]. In patients with 
clear cell EC, there is ΕrbB-2 receptor overexpression in 33% of  
cases and ΕrbB-2 gene amplification in 16-50% of  cases [34, 35, 
42, 48, 51].
ErbB-3 localized to surface epithelial cells of  endometrium [31-
36, 53, 54]. It is located in the cytoplasm, with membrane staining 
in a minority of  samples [28, 32-36, 54].
ErbB-4 localized to epithelial and stromal cells of  endometrium 
[31-36, 54, 55]. It is located in the cytoplasm, with membrane 
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Figure 1. Signaling pathways of  ErbB receptors [4, 13, 15, 19-27].
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staining in a minority of  samples [28, 32-36, 54].
Clinical role of  ErbB receptors in EC
Recent years, the clinical role of  ErbB receptors (especially EGFR 
and ΕrbB-2) in EC patients, have increasing popularity [35, 36, 42, 
44, 45, 56-58].
EGFR may have a dual role in EC [42]. EGFR overexpression did 
not affect disease progression in patients with type I EC, although 
affects disease progression in Type II EC [42]. More specifically 
EGFR overexpression in patients with Type II EC, associated 
with high grade disease and adverse clinical outcome [34, 35, 42, 
44, 45].
Moreover, ΕrbB-2 overexpression especially in patients with Type 
II EC, is an indicator of  a highly aggressive disease with poor 
overall survival [34, 35, 44, 45, 47, 48, 50, 59, 60].
ErbB-3 overexpression in patients with EC, has an unclear clini-
cal role and not well studied [28, 44, 45, 54, 61]. The clinical role 
of  ErbB-4 in patients with EC, is poorly understood and not well 
studied [28, 32-35, 44, 45 ,54, 62]. It is obvious that ErbB recep-
tors (especially EGFR and ΕrbB-2) in EC patients, are potential 
targets of  molecular targeted therapies [35, 36, 42, 44, 45, 56, 58, 
63]. Anti-ErbB MoAbs (cetuximab, panitumumab, trastuzumab, 
pertuzumab) may be an attractive treatment option, especially in 
EC patients with advanced, recurrent or metastatic disease and 
overexpression of  EGFR and ErbB-2 [6, 7, 34-36, 44, 56, 64, 65].
However, a phase II study (NCT00392769) failed to demonstrate 
significant activity of  cetuximab in unselected EC patients with 
advanced or recurrent disease [66, 67]. The clinical efficacy of  
trastuzumab in EC, has been reported in several case reports 
[64, 68-70]. However, a phase II study of  Gynecologic Oncology 
Group (GOG-181B) failed to demonstrate significant activity of  
trastuzumab in unselected EC patients with advanced or recur-
rent disease and overexpression of  ErbB-2 [71]. Moreover, an on-
going randomized phase II study (NCT01367002) evaluates the 
efficacy of  carboplatin/paclitaxel with or without trastuzumab in 
selected EC patients (papillary serous) with advanced or recurrent 
disease and overexpression of  ErbB-2 [72].
ErbB-specific TKIs (gefitinib, erlotinib, lapatinib, afatinib) may be 
another attractive treatment option in EC patients with advanced, 
recurrent or metastatic disease and overexpression of  EGFR and 
ErbB-2 [34-36, 44, 45, 56, 73-75]. However, a phase II study of  
the Gynecologic Oncology Group (GOG-229C) failed to dem-
onstrate significant activity of  gefitinib in unselected EC patients 
with persistent or recurrent disease [75]. Also, a phase II study 
(NCIC IND-148) failed to demonstrate significant activity of  
erlotinib in unselected EC patients with advanced or metastatic 
disease [74].
Moreover, a phase II study of  the Gynecologic Oncology Group 
(GOG-229D) failed to demonstrate significant activity of  lapat-
inib in unselected EC patients with persistent or recurrent disease 
[73]. It is obvious that ErbB-targeted therapies have only modest 
effect in unselected EC patients [34, 35, 44, 45, 56, 58, 63, 76]. 
Further studies into the molecular pathways of  EC, may increase 
our knowledge regarding ErbB receptors and ErbB-targeted ther-
apies [34, 44]. Perhaps the clinical role of  ErbB receptors is more 
important in type II EC patients [34, 35, 44, 45, 47, 48, 50, 59, 60]. 
Also, ErbB-targeted therapies may be more effective as adjuvant 
treatment in type II EC patients with EGFR and ErbB-2 over 
expression [35, 36, 42 ,44 ,56-58, 64, 68, 69, 71-81].
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